文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

静脉注射免疫球蛋白联合甲泼尼龙减轻COVID-19呼吸系统疾病负担

Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019.
PubMed 文献 · Crit Care Explor · 2020-11-16
一句话结论在A-a梯度>200 mmHg的COVID-19肺炎低氧患者中,早期IVIG联合甲泼尼龙可显著减少机械通气需求并缩短住院和ICU时间。

这项前瞻性随机开放标签先导试验纳入33例COVID-19肺炎低氧患者,1:1随机接受标准治疗+IVIG 0.5 g/kg/d联合甲泼尼龙40 mg预处理3天,或单纯标准治疗。作者结论为IVIG可改善A-a梯度>200 mmHg患者的低氧并减少机械通气进展,需III期多中心双盲试验验证。

要点

  • 在入组时A-a梯度>200 mmHg的COVID-19肺炎低氧患者中,IVIG组机械通气进展率显著低于标准治疗组(2/14 vs 7/12,p=0.038)。
  • 同一亚组中,IVIG组中位住院时间缩短(11 vs 19天,p=0.01),中位ICU停留时间缩短(2.5 vs 12.5天,p=0.006)。
  • 方案为IVIG 0.5 g/kg/d,输注前30分钟给予甲泼尼龙40 mg,疗程3天。

适用人群与场景

  • 亚组分析限定入组时A-a梯度>200 mmHg的患者(IVIG组14例,标准治疗组12例)。

诊断标准与关键阈值

  • 低氧的COVID-19肺炎患者纳入研究,具体低氧定义原文未提及。
  • 亚组分析阈值:入组时A-a梯度>200 mmHg。

处置流程与药物剂量

  • 第一步:筛选低氧的COVID-19肺炎住院患者,评估A-a梯度。
  • 第二步:干预组在标准治疗基础上接受IVIG 0.5 g/kg/d静脉输注,输注前30分钟给予甲泼尼龙40 mg,疗程3天。
  • 第三步:对照组仅接受标准治疗。
  • 第四步:监测机械通气需求、PaO2/FiO2、住院和ICU时间。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • A-a梯度>200 mmHg亚组:IVIG组机械通气进展率2/14 vs 标准治疗组7/12,p=0.038(Fisher精确检验)。
  • A-a梯度>200 mmHg亚组:IVIG组中位住院时间11天 vs 标准治疗组19天,p=0.01(Mann-Whitney U检验)。
  • A-a梯度>200 mmHg亚组:IVIG组中位ICU停留时间2.5天 vs 标准治疗组12.5天,p=0.006(Mann-Whitney U检验)。
  • 标准治疗组中接受糖皮质激素治疗者的第7天PaO2/FiO2改善显著低于IVIG组(p=0.0057,Mann-Whitney U检验)。
  • 不良事件原文未提及。

证据类型、等级与局限

  • 证据类型:前瞻性随机开放标签先导试验(pilot study)。
  • 局限:样本量小(33例)、单中心、开放标签设计;作者指出需III期多中心随机双盲临床试验验证。

对床旁实践的改变

  • 对于COVID-19肺炎低氧且A-a梯度>200 mmHg的患者,可考虑在标准治疗基础上早期使用IVIG 0.5 g/kg/d联合甲泼尼龙40 mg预处理3天,以降低机械通气进展风险并缩短住院和ICU时间。
  • 总体低氧COVID-19肺炎人群的机械通气需求未显示显著获益(p=0.12),提示应基于A-a梯度选择性使用。
  • 该方案来自小样本先导试验,需III期多中心双盲试验验证后方可作为常规推荐。
  • 常见陷阱:不应将先导试验的亚组结果外推为所有COVID-19肺炎患者的通用治疗;糖皮质激素单用(标准治疗组中接受者)的PaO2/FiO2改善低于IVIG联合方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Dysregulated neutrophil and platelet interactions mediate immunothrombosis and cause lung injury in coronavirus disease 2019. IV immunoglobulin modulates neutrophil activation through FcγRIII binding. We hypothesized that early therapy with IV immunoglobulin would abrogate immunothrombosis and improve oxygenation and reduce progression to mechanical ventilation in coronavirus disease 2019 pneumonia.

DESIGN: Prospective randomized open label.

SETTING: Inpatient hospital.

PATIENTS AND INTERVENTION: Hypoxic subjects with coronavirus disease 2019 pneumonia were randomized 1:1 to receive standard of care plus IV immunoglobulin 0.5 g/kg/d with methylprednisolone 40 mg 30 minutes before infusion for 3 days versus standard of care alone.

MAIN RESULTS: Sixteen subjects received IV immunoglobulin and 17 standard of care. Median ages were 51 and 58 years for standard of care and IV immunoglobulin, respectively. Acute Physiology and Chronic Health Evaluation II and Charlson comorbidity scores were similar for IV immunoglobulin and standard of care. Seven standard of care versus two IV immunoglobulin subjects required mechanical ventilation (p = 0.12, Fisher exact test). Among subjects with A-a gradient of greater than 200 mm Hg at enrollment, the IV immunoglobulin group showed: 1) a lower rate of progression to requiring mechanical ventilation (2/14 vs 7/12, p = 0.038 Fisher exact test), 2) shorter median hospital length of stay (11 vs 19 d, p = 0.01 Mann Whitney U test), 3) shorter median ICU stay (2.5 vs 12.5 d, p = 0.006 Mann Whitey U test), and 4) greater improvement in Pao2/Fio2 at 7 days (median [range] change from time of enrollment +131 [+35 to +330] vs +44·5 [-115 to +157], p = 0.01, Mann Whitney U test) than standard of care. Pao2/Fio2 improvement at day 7 was significantly less for the standard of care patients who received glucocorticoid therapy than those in the IV immunoglobulin arm (p = 0.0057, Mann Whiney U test).

CONCLUSIONS: This pilot study showed that IV immunoglobulin significantly improved hypoxia and reduced hospital length of stay and progression to mechanical ventilation in coronavirus disease 2019 patients with A-a gradient greater than 200 mm Hg. A phase 3 multicenter randomized double-blinded clinical trial is under way to validate these findings.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Sakoulas G, Geriak M, Kullar R, et al. Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019. Crit Care Explor. 2020. PMID: 33225306. doi:10.1097/CCE.0000000000000280

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。